Yes, mumps can cause sterility in males, but only in a minority of cases and almost exclusively when the infection triggers orchitis, a painful inflammation of the testicles. Before widespread vaccination, mumps orchitis struck roughly 20 to 30 percent of infected post-pubertal males, per CDC surveillance data, and testicular atrophy followed in about 30 to 50 percent of those orchitis cases. Actual infertility, however, is far rarer than atrophy suggests, because most men retain enough functioning tissue in at least one testicle to keep sperm counts in the fertile range.
The mechanism: how the virus reaches the testicle
Mumps is caused by a rubulavirus spread through respiratory droplets. The virus first replicates in the upper respiratory tract, then seeds the bloodstream during a brief viremia roughly 12 to 25 days after exposure. From the blood it settles in glandular tissue with high ductal flow, which is why the parotid salivary glands and the testicles are preferred targets.
The testicle is not built to tolerate inflammation. Its seminiferous tubules, where sperm production occurs, sit behind the blood-testis barrier, a tight junction system that normally shields developing sperm from immune cells. Mumps virus infection of Sertoli cells disrupts that barrier. Immune cells flood in, the testicle swells against its rigid fibrous capsule, and local pressure rises.
That pressure is the core injury. The tunica albuginea capsule cannot stretch much, so swelling compresses the tiny capillaries feeding the seminiferous tubules. Ischemia follows. Sustained oxygen deprivation kills germ cells and, in severe cases, Leydig cells, the testosterone-producing cells sitting between the tubules.
In plain terms: the virus does not eat the testicle directly. It provokes an immune response that strangles local blood flow, and the resulting oxygen starvation does the damage.
Two consequences follow. Germ cell loss lowers sperm output. If enough tubules are destroyed and replaced by scar tissue, sperm production drops permanently. Leydig cell damage is less common but explains why a small fraction of affected men also develop low testosterone.
The numbers: orchitis rates, atrophy rates, and fertility outcomes
The table below reconciles the figures that circulate in reviews, which often confuse three different endpoints: orchitis, atrophy, and infertility.
| Stage in the chain | Typical rate | What it measures |
|---|---|---|
| Mumps infection in unvaccinated post-pubertal males | 100 percent (reference group) | Baseline infection |
| Orchitis after mumps | 20–30 percent | Clinical testicular inflammation |
| Testicular atrophy after orchitis | 30–50 percent | Measured shrinkage of the gland |
| Abnormal sperm parameters after orchitis | 30–50 percent | Reduced count, motility, or quality |
| Persistent infertility after mumps orchitis | 1–13 percent, most estimates under 5 percent | Failure to father a child |
These figures do not conflict; they measure different events along one chain. Roughly one in four infected men gets orchitis, roughly two in five of those develop measurable atrophy, and only a small fraction of the atrophy group ends up truly infertile. Multiply the ranges and the population-level infertility risk from mumps lands near 1 percent or below.
A less obvious detail: unilateral orchitis, involving one testicle, is the common case and carries a much better prognosis than bilateral disease. The remaining healthy testicle typically undergoes compensatory hypertrophy, increasing its output to cover the loss. Bilateral orchitis occurs in roughly 10 to 30 percent of orchitis cases and is where most of the true sterility risk concentrates.
Sperm count recovery is also the rule, not the exception. In follow-up studies of men with mumps orchitis, most who had depressed sperm counts at three months showed improvement by twelve months. Persistent azoospermia, meaning no sperm in the ejaculate, is uncommon and usually tied to bilateral severe atrophy.
Bilateral versus unilateral orchitis: why side matters
The two testicles operate with enormous functional reserve. A single healthy testicle produces enough sperm to maintain normal fertility in the great majority of men. This reserve is why unilateral mumps orchitis rarely causes sterility and why counseling should not treat every case as a fertility emergency.
Bilateral involvement changes the arithmetic. If both testicles lose 50 percent of germ cell function, combined output may fall below the fertile threshold. Severe bilateral atrophy, where both glands shrink markedly, is the scenario most associated with persistent azoospermia and elevated follicle-stimulating hormone, a marker of germ cell failure.
A counterintuitive point about timing: the severity of acute swelling does not reliably predict later fertility. Some men with modest initial symptoms develop pronounced atrophy, while others with dramatic acute orchitis recover fully. This is why sperm analysis, not the intensity of the original illness, is the useful prognostic tool.
How long damage takes: the orchitis-to-fertility timeline
The time course matters for anyone wondering when to test or worry. The table below maps the typical sequence.
| Time point | What happens | Clinical meaning |
|---|---|---|
| Day 0 | Parotid swelling begins; orchitis usually follows 4–8 days later | Orchitis rarely precedes parotitis |
| Days 1–5 of orchitis | Peak swelling, pain, fever up to 103–104°F | Acute ischemic injury window |
| Weeks 2–6 | Swelling resolves; atrophy may begin | Shrinkage often first noticed here |
| Months 1–3 | Sperm parameters at their worst | Early semen analysis can look falsely bleak |
| Months 6–12 | Most recovery occurs | Repeat semen analysis at 6 and 12 months |
| Beyond 12 months | Plateau; persistent abnormalities likely permanent | Fertility counseling and options |
The practical takeaway from this timeline: a poor semen analysis at six weeks is not a verdict. Waiting until at least three months, when a full spermatogenic cycle has turned over, gives a more honest picture. Confirming with a second analysis at six to twelve months is standard practice.
The vaccine question: how much protection, and where it fails
Mumps vaccination is the single most effective preventive step, but its protection is imperfect and wanes. The measles-mumps-rubella vaccine is about 88 percent effective against mumps after two doses, per CDC estimates, lower than its protection against measles or rubella. Outbreaks among vaccinated young adults, documented on college campuses in the 2010s, reflect this waning rather than vaccine failure at administration.
Even so, vaccinated men who do contract mumps have substantially lower orchitis rates than unvaccinated men. The reduced viral load and blunted immune response appear to limit testicular involvement. One professional caveat worth stating plainly: because vaccine-induced immunity fades over decades, a man vaccinated in childhood may still be susceptible in his twenties, precisely the age when orchitis risk is highest.
Correcting the myths: what mumps sterility is not
Several widespread beliefs overstate or misstate the risk.
Mumps does not automatically cause sterility, and most infected men father children normally. The 20 to 30 percent orchitis figure describes inflammation, not infertility, and conflating the two inflates fear.
Sterility is not guaranteed by atrophy. Shrinkage means tissue loss, but functional reserve in the remaining tissue often preserves fertility. Atrophy is a warning sign, not a diagnosis of sterility.
Mumps orchitis is not the only cause of male factor infertility, and treating it as a singular threat distorts priorities. Varicocele, genetic factors, and other infections account for far more infertility cases overall.
Finally, adult mumps is not uniformly worse than childhood mumps for fertility, though it is worse for orchitis risk. Pre-pubertal infection rarely involves the testicles at all, because the gland's structure and blood supply differ before puberty.
What to actually do: prevention and post-orchitis steps
For prevention, confirm two MMR doses, especially for men in their teens and twenties who may have waning immunity. During an outbreak, public health guidance may recommend an additional dose.
If orchitis develops, these steps matter during the acute window:
- Rest and scrotal elevation to reduce swelling and pressure on the capsule.
- Cold packs applied intermittently for the first 48 to 72 hours.
- Pain and fever control with nonsteroidal anti-inflammatory drugs, unless contraindicated.
- Prompt medical evaluation if testicular pain is severe, sudden, or accompanied by nausea, since testicular torsion is a surgical emergency that mimics orchitis.
- Avoid strenuous activity until swelling resolves, typically one to two weeks.
After recovery, if fertility is a concern, obtain a semen analysis no earlier than three months after the acute illness, then repeat at six and twelve months if results are abnormal. Men with bilateral orchitis or marked atrophy should discuss referral to a reproductive urologist.
Red-flag symptoms that warrant urgent care, not watchful waiting:
- Sudden severe testicular pain, especially with vomiting, suggesting torsion rather than orchitis.
- High fever above 104°F or signs of systemic infection.
- A testicle that becomes hard, fixed, or develops a new lump weeks after recovery.
- Inability to urinate or worsening scrotal redness and warmth.
- Persistent low libido, fatigue, or loss of body hair months later, which may signal Leydig cell failure and low testosterone.
Limits of the evidence
Much of the mumps fertility literature comes from outbreaks before routine vaccination and from small case series, not large prospective trials. The atrophy and infertility percentages vary widely across studies because definitions differ and follow-up is inconsistent. Modern vaccinated populations have lower orchitis rates, so older numbers may overstate today's risk.
The honest summary is this: mumps can cause sterility in males through orchitis-driven ischemic injury, but the probability is low in any individual case, concentrated in bilateral severe disease, and usually detectable through semen analysis rather than assumed from a diagnosis. Prevention through vaccination remains the highest-value action, and sperm testing three to twelve months after orchitis remains the most reliable way to know where a man actually stands.